PHOENIX--(BUSINESS WIRE)--Jan. 5, 2006--Zila, Inc., (Nasdaq: ZILA), has enrolled the first patients in its Phase III clinical trial for OraTest, its oral cancer detection drug. Zila began its new Phase III clinical trial after reaching an agreement under the United States Food and Drug Administration’s Special Protocol Assessment process.
